Effect on Non-Alcoholic Fatty Liver Disease With Advanced Fibrosis in Patients With Type 2 Diabetes Mellitus on Treatment With Gastric Inhibitory Polypeptide / Glucagon Like Peptide-1 Analogue (Tirzpatide)
Obesity and type 2 Diabetes Mellitus prevalence has doubled in the last 30 years and nearly one fifth of UAE population has Type 2 Diabetes while more than quarter has obesity. Non-alcoholic fatty liver disease is present in more than 30% of patients with type 2 diabetes and in \> 50% patient with obesity 20% of patients with Non-alcoholic fatty liver disease progress to develop non-alcoholic steatohepatitis which can lead to liver failure and hepatocellular carcinoma. This study aims to use GLP-1 analogue to see effects on liver fat deposition after six months of treatment There is no current randomised study on treatment of non-alcoholic steatohepatitis in United Arab Emirates population; so once completed this will the first study. This study will pave the way for developing a treatment pathway for patients with non-alcoholic fatty liver disease.
• Age \> 18; either male or female
• Diagnosed to have Type 2 Diabetes Mellitus for \> 1 year.
• Presence of NAFLD advanced fibrosis (F3 and F4; defined by NFS of \> 0.676)
• Able to consent independently
• Not already on GLP-1 analogues or SGLT2 inhibitors or pioglitazone
• Good general health
• BMI\> 19 but less than 40